Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal
- PMID: 19996005
- DOI: 10.2215/CJN.02720409
Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal
Abstract
Because inflammation by now is a "traditional" finding that predicts poor outcome and cardiovascular events in the vast majority of patients with ESRD, it could be argued that inflammatory biomarkers should not longer be considered "novel" risk factors. In this review, we forward the hypothesis that, in addition to putative direct proatherogenic effects, persistent inflammation may serve as a catalyst and, in the toxic uremic milieu, modulate the effects of other concurrent vascular and nutritional risk factors. We discuss some recent observational studies, suggesting that the presence of persistent inflammation magnifies the risk for poor outcome via mechanisms related to self-enhancement of the inflammatory cascade and exacerbation of both the wasting and the vascular calcification processes. Because persistent inflammation may be the silent culprit of other commonly observed pathophysiologic alterations in chronic kidney disease, it is imperative that inflammatory markers be regularly monitored and therapeutic attempts be made to target persistent low-grade inflammation in this patient group.
Similar articles
-
Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.J Nephrol. 2009 Nov-Dec;22(6):774-82. J Nephrol. 2009. PMID: 19967657
-
Inflammation as a risk factor and target for therapy in chronic kidney disease.Curr Opin Nephrol Hypertens. 2011 Nov;20(6):662-8. doi: 10.1097/MNH.0b013e32834ad504. Curr Opin Nephrol Hypertens. 2011. PMID: 21825982 Review.
-
Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.Scand J Urol Nephrol. 2004;38(5):405-16. doi: 10.1080/00365590410031715. Scand J Urol Nephrol. 2004. PMID: 15764253 Review.
-
Biochemistry and biomarkers of inflamed patients: why look, what to assess.Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S56-63. doi: 10.2215/CJN.03090509. Clin J Am Soc Nephrol. 2009. PMID: 19996007 Review.
-
[Chronic inflammation and cardiovascular risk in hemodialysis].G Ital Nefrol. 2003 Nov-Dec;20(6):631-40. G Ital Nefrol. 2003. PMID: 14732917 Review. Italian.
Cited by
-
Immune dysfunction in uremia—an update.Toxins (Basel). 2012 Oct 24;4(11):962-90. doi: 10.3390/toxins4110962. Toxins (Basel). 2012. PMID: 23202302 Free PMC article. Review.
-
Low T3 syndrome and long-term mortality in chronic hemodialysis patients.World J Nephrol. 2015 Jul 6;4(3):415-22. doi: 10.5527/wjn.v4.i3.415. World J Nephrol. 2015. PMID: 26167466 Free PMC article.
-
Restless Legs Syndrome in Chronic Kidney Disease: Is Iron or Inflammatory Status To Blame?J Clin Sleep Med. 2019 Nov 15;15(11):1629-1634. doi: 10.5664/jcsm.8028. J Clin Sleep Med. 2019. PMID: 31739853 Free PMC article.
-
Painless myocardial ischemia is associated with mortality in patients with chronic kidney disease.Nephron Clin Pract. 2012;122(1-2):9-16. doi: 10.1159/000347143. Epub 2013 Mar 1. Nephron Clin Pract. 2012. PMID: 23466572 Free PMC article.
-
The uremic toxin indoxyl sulphate enhances macrophage response to LPS.PLoS One. 2013 Sep 30;8(9):e76778. doi: 10.1371/journal.pone.0076778. eCollection 2013. PLoS One. 2013. PMID: 24098806 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical